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AUDITING  THE  PRODUCER  PRICE  INDEX: 
MICRO  EVIDENCE  FROM  PRESCRIPTION  PHARMACEVTICAL  PREPARATIONS 
ABSTRACT 
In this  paper  we  focus  on a mystery  we  uncovered  while  undertaking  a detailed  audit of  the 
US  Bunau  of  Labor  Sttistics  producer  price  index  (PPI).  We  summarize  our  puzzle  as  follows. 
From  January  1984 through  December  1989. the BLS  price  index  for  SIC  28341  (pnscriplion 
pharmaceutical  preparations)  grew  at an annual rate of  9.09%.  For  purposes  of comparison,  we  have 
ob0incd  monthly  price  and quanlity  sales  data on all prcscriptlon  pha~acculical  preparation  products 
sold  by  four  major  US  phannaccutlcal  manufacturers,  accounting  for  about 24%  of  lotal lnduslry 
domestic  sales  in  1989.  Using  Laspcyrcs  price  Index  construction  procedures  on these  data that mimic 
BLS  methods,  we  fud  that over  the same  lime period,  the four-company  price  Index increased  LI only 
6.68% per year.  Finally, when we employ a Divislr  price index proccdun with smoothed  weights  ti 
incorporates  new goods  immediately,  the aggregate  price index for these  four firms grows a~  a CPIC  of 
only  6.03% per year. 
Why  is it that the official  BLS price index grows approximately 50% more rapidly (9.09% vs. 
6.03%) than the Divisia price index? That mystery Is lhc focal point of our paper. 
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“~11  index  numbers  which  are  not  freakish  or  biased 
practically  agree  vlth  eech  other.” 
Irving  Fisher1 
1.  INTBODUCTION 
In  this  paper  ve  focus  on  a  mystery  ve  uncovered  vhila  undertsklng  a  ’ 
detailed  audit  of  the  US  Bureeu  of  Labor  Statistics  producer  price  index  (PPI). 
Our  puzzle  is  summarized  in  Figure  1  below.  From January  1984  through  December 
1989,  the  BLS  price  index  for  SIC  28341  (prescription  pharmaceutical 
prepartions)  grev  at  an  annual  rate  of  9.09%.  For  purposes  of  comparison,  ve 
have  obtained  monthly  price  and  quantity  sales  data  on  all  2,090  prescription 
pharmaceutical  preparation  products  sold  by  four  major  pharmaceutical  oanufac- 
(Insert  Figure  1  Near  Here) 
turers  in  the  US,  accounting  for  about  24X  of  total  domestic  industry  sales  in 
1989.  Using  BLS-type  Laspeyres  price  index  construction  procedures  on  these 
data  4th  spliced  fixed  vefghtse2  we  find  that  over  the  same  time  period,  the 
four-company  price  index  increased  at  only  6.68%  per  year.  Finally,  vhen  we 
employ  a  Divisia  price  index  procedure  that  incorporates  new  goods  immediately, 
the  aggregate  four-firm  price  index  grovs  at  a  rate  of  only  6.03%  per  year.  Uhy 
Is  it  that  the  BLS price  index  grows  approximately  50% more  rapidly  (9.09%  VS. 
6.03X)  than  the  Divisia  price  index?  This  mystery  is  the  focal  point  of  our 
paper.  3 
A  number  of  factors  could  account  for  the  difference.  First,  our  four 
firms  could  be  unrepresentative  of  the  industry  as  a  whole.  Second,  the 
products  and  firms  sampled  by  the  BLS  could  be  unrepresentative  of  industry 
transactions.  This  sampling  discrepancy  could  reflect  the  fact  that Index  Value AUDITING  THE  PRODUCER  PRICE  INDEX  -  Page  2  - 
participation  by  firma  in  providing  Its  price  date  ia  voluntary.  ~lro,  sampling 
procedurea  used  by  the  BIS  might  not  capture  l dequetaly  the  price  trends  of  new 
producta,  particularly  in  industries  cheracteriaed  by  rapid  technological 
change.  Third,  the  prices  reported  by  the  firma  to  the  BLS  might  differ  from 
the  firma’  actual  average  transactions  pricea.4  Fourth,  use  of  fixed  veight 
price  indexer  such  aa  the  Laapeyrea  might  result  in  rather  different  grovth 
rater  from  those  baaed  on  chained  procedures  such  as  the  Diviaie  index,  Note 
thet  one  would  not  expect  unmeaaured  quality  changes  to  account  for  the 
difference,  since  none  of  the  three  indexes  reported  above  connects  generics  to 
their  patented  antecedenta.  nor  doer  any  compare  wimprovedw  drugs  to  their 
predecessors  and  adjust  the  price  index  accordingly  using,  for  example,  hedonic 
ae thoda . 
Our  interest  in  the  reliability  of  official  producer  price  indexes  stems 
from  a  aore  general  research  interest  in  the  oeaaurement  of  output  and 
productivity  growth.  Given  the  esaential  identity  betveen  value  of  sales  and  a 
price  index  timer  a  quantity  index.  any  errors  in  the  PPI  have  important 
implications  for  the  accuracy  of  measured  rates  of  inflation,  real  output 
changes,  real  inveatment,  and  grovth  in  productivity. 
To  begin  eaaeaaing  the  reliability  of  the  PPI,  ve  decided  to  audit  one 
industry  in  detail.  Our  choice  of  the  pharmaceutical  preparations  industry  vas 
affected  by  the  fact  that  this  industry  is  one  in  vhich  technological  change  is 
significant,  its  pricing  of  products  has  been  the  focus  of  considerable  public 
attention,  it  her  other  attributes  of  interest  to  us  (for  example,  it  is  heavily 
engaged  in  research  and  development),  and,  on  a  practical  basin,  arrangements 
could  be  made to  have  proprietary  micro  data  made available  for  analysis.  It  is 
worth  noting  that  our  analysis  is  confined  to  the  PPI  for  this  industry,  and  ve 
do  not  examine  issuer  involving  the  Consumer Price  Index  (CPI),  for  vhich  a 
sample  of  prescription  pharmaceutical  prices  drawn  at  the  retail  and  hospital AUDITING  THE  PRODUCER  PRICE  INDEX  -  Page  3  - 
levels  would  be  required.  However,  some  of  the  important  issues  involving  the 
treatment  of  generics  and  new goods  may  be  similar  for  the  PPI  and  CPI. 
We start  our  paper  in  Section  II  with  a  brief  overview  of  the  PPI;  a  aore 
detailed  discussion  is  found  in  Appendix  A  to  this  paper.’  In  Section  111  we 
provide  a  summary  of  the  four  anonymous pharmaceutical  manufacturers,  comment on 
another  source  of  data  (MS  America)  that,  for  one  significant  sub-class  of 
pharmaceutical  preparations  (systemic  anti-infectives),  encompasses  almost  the 
entire  universe  of  products  sold  domestically,  and  prerent  some  preliminary 
empirical  findings  involving  data  comparisons.  The  principal  results  of  our 
empirical  analysis  are  presented  in  Section  IV,  and  there  we  report  on  our 
various  attempts  to  unravel  this  mystery.  In  Section  V  we  address  the  “youthful 
goods”  problem  in  further  detail,  Finally,  in  Section  VI  we  summarize  our 
findings  and  describe  our  agenda  for  further  research. 
II.  wm  INDEX  FOR  SIC  2834J 
The  PPI  is  one  of  the  oldest  continuous  statistical  data  systems  published 
by  the  BIS,  although  until  1978  it  was known  as  the  Wholesale  Price  Index  (UPI). 
The  first  WPI,  published  for  the  base  period  1890-1899,  was an  unweighted 
average  of  price  relatives  for  about  2S0  commodities.  Since  that  tioe,  aany 
changes  have  been  made,  including  alterations  in  the  sample  of  comaodities,  the 
base  period,  and  the  method  of  calculating  the  index.  According  to  the  U.S. 
Department  of  labor  [1988,  p,  1251,  the  1978  name change  from  UP1 to  PPI  “...Vas 
intended  to  reemphasize  that  the  industrial  price  program  continues  to  be  based 
on  prices  received  by  producers  from  whoever  makes the  first  purchase,  rather 
than  on  prices  paid  to  wholesalers  by  retailers  or  others  further  removed  in  the 
distribution  chain.”  Currently  the  PPI  program  at  BLS encompasses the 
construction  of  aggregate  price  indexes  for  almost  SOD mining  and  manufacturing 
industries,  including  approximately  8,000  indexes  for  specific  product AUDITING  THE  PRODUCER  PRICE  INDEX  -  Page  4  - 
categories,  based  on  reports  from  epproximatoly  23,000  reaponding  companies. 
The  BLS  computes  and  publiahes  an  overall  price  index  for  phermeceuticel 
preperetions  (Standard  Induatriel  Clesaificetion  [SIC]  code  2834),  for 
prescription  pharmaceuticels  (SIC  28341).  and  for  roughly  50  sub-groupa  from  the 
seven  to  nine-digit  SIC  level;  a  complete  list  of  product  classes  reported  by 
the  BLS  in  SIC  28341  ia  given  in  Table  1  below.6 
Teble  1 
Industries  in  SIC  28341  for  which  the  BLS Publishes  Monthly  Price  Indexer 
1984.19 
SIC  w.R 
Phermaceutical  Preper*tibns  2834 
Phermeceuticel  prepara- 
tions,  prescription8  2834  1 
Analgesics  2834  102 
Narcotics  l nalgesics  2834  1021 
Codeine  and 
Combinations  2834  10211 
Non-narcotic  l nslgeaica  2834  1022 
Aspirin,  APC  6  related  2834  10229 
Antiarthritics  2834  105 
Anticoagulents  2834  106 
Anticonvulsants  2834  107 
Systemic  antihistamines  2834  109 
Systemic  l ntiinfectives  2834  111 
Broed  and  aedium 
aprctrum  antibiotics  2834  1111 
Cephalosoporins  2834  11111 
Broad  spectrum 
penicillins  2834  11112 
Erythromycins  2834  11113 
Tetrecyclines  2834  11114 
Other  broad  end  medium 
spectrum  antibiotics  2834  11119 
Systemic  penicillins  2834  11129 
Urinary  antibacteriala  2834  11139 
Antispesmodic/antiaecretory  2834  116 
Bronchial  rherapy  2834  118 
Cancer  therapy  products  2834  119 
Cardiovascular  therapy  2834  121 
Antihypertensive  drugs  2834  12119 
Vaaodilators  2834  12129 
Other  cardiovasculara  2834  12191 
Industrve  Codq 
CNS stimulents  2834  123 
Contreceptives  2834  124 
Cough &  cold  preparations  2634  125 
Naael  decongestants  2834  12512 
Dermatological  preparationa  2834  126 
Acne  preparations 
Fungicides 
Topic  antiinfectivea 
Antipruritica 
Diebetes  therepy 
Diuretics 
Hormones 
Hospital  l olutions 
I.V.  solutions  50  ml 
and  under 
tluscle  relaxants 
Nutrients  and  supplements 




Hafor  tranquiliters 





Hlacelleneous  prescription 
2834  12611 
2834  12619 
2834  12631 
2834  12641 
2834  127 
2834  128 
2834  135 
2834  136 
2834  13604 
2834  139 
2834  141 
2834  142 
2834  144 
2834  1441 
2834  14411 
2834  14412 
2834  1442 
2834  145 
2834  148 
2834  14819 
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The  PPI  for  the  various  pharamaceutfal  products  ara  based  on  prices  for  a 
fixed  basket  of  products,  dravn  from  monthly  voluntary  reporting  to  the  BLS  by 
selected  manufacturing  establishments.  Several  points  are  worth  noting. 
First,  the  fixed  basket  of  products  is  chosen  through  a  sampling  procedure 
implemented  at  irregular  intervals  across  industries,  vhose  frequency  depends  in 
part  on  the  perceived  stability  of  the  industry.  Detailed  surveys  of 
pharmaceutical  firms  vere  conducted  in  1980  and  in  1987,  and  the  fixed  baskets 
were  changed  in  1981  and  in  January  1988;  the  BLS  refers  to  the  1980  survey  as 
“Cycle  I”.  and  that  from  1987  as  “Cycle  II”. 
Second,  in  principle,  the  sample  is  drawn  from  the  universe  of  all 
products  from  domestic  establishments  vhoae  main  production  is  in  SIC  2834.7  A 
BLS field  representative  visits  selected  establishments  (in  the  pharmaceutical 
industry,  the  BLS  visits  wherever  the  appropriate  records  are  kept,  usually  ’ 
company  headquarters)  during  the  survey  year,  and  uses  a  procedure  called 
“disaggregation”  to  settle  on  vhich  detailed  products  are  to  be  sampled.  Once 
this  initial  visit  is  completed,  subsequent  “repricing’  for  the  selected  commod- 
ities  occurs  on  a  monthly  basis,  typically  by  the  respondent  company  filling’out 
and  returning  forms  sent  it  by  mail  by  the  BLS;  these  forma  are  pro-printed  with 
the  detailed  description  of  the  chosen  products.  the  reported  prices  over  the 
previous  three  or  four  months,  and  a  request  for  a  price  quote  fron  the  Tuesday 
of  the  week  containing  the  13th  of  the  month.  Currently,  approximately  50 
responding  companies  in  SIC  28341  provide  about  400  individual  price  quotations. 
Third,  once  monthly  data  are  in  hand,  the  BLS  calculates  thr  PPI  according 
to  a  modified  Laspeyres  formula,  details  of  which  are  given  in  Appendix  A. 
Fourth,  during  the  disaggregation  process,  products  are  defined  in  very 
specific  detail.  As  the  U.  S.  Department  of  Labor  (1986a,  1989)  manuals 
emphasize,  any  price-determining  characteristic  distinguishes  one  product  from AUDITING  THE  PRODUCER  PRICE  INDEX  -  Page  6  - 
another.  The  U.  S.  Department  of  Labor  [1988,  p.  1261  rummarinoa  price- 
dotormining  characteristics  as  follows: 
‘If  a  company  charges  more  for  a  red  widget  than  a  white  one, 
color  is  one  of  the  price-determining  variables;  if  all  widgets 
sell  for  the  #ame price  regard1088  of  color,  color  is  not  a 
price-determining  variable.' 
In  the  pharmaceutical  context,  if  prices  of  bottles  differ,  a  bottle  of  100 
pills  each  having  SO milligrams  of  a  drug  is  not  the  same as  a  bottle  of  SO 
pills  of  100  milligrams,  even  though  both  bottles  contain  5,000  milligrams  of 
the  #ame  drug.  Noreover,  transaction-specific  factors  such  as  volume  discounta 
or  freight  costs  (if  absorbed  by  the  manufacturer)  affect  price,  so  these 
factors  are  included  in  the  definition  of  the  product. 
Sixth,  precisely  hov  the  BLS determines  the  total  number  of  price 
quotations  assigned  to  each  establishment  is  not  completely  clear,  but 
apparently  thin  decision  involves  substantial  judgment.  According  to  the  US 
Department  of  Labor  [1986b.  pp.  42-461,  the  number  of  quotes  taken  from  an 
establishment  depends  on  industry  concentration,  price  variations  vithln  and 
across  establishments,  establishment  size,  and  the  number  of  products  produced 
at  each  establishment.  Moreover,  discussions  with  BLS personnel  suggest  that 
for  any  sampled  establishment  in  any  industry,  there  is  a  minimum of  tvo  quotes 
and  a  maximum  of  sixteen.  In  recent  years,  the  number  of  companies  sampled  has 
declined  vithtn  the  pharmaceutical  industry,  there  has  been  an  effort  to 
increase  quotes  to  large  sample  units  and  to  distribute  quotes  across  product 
lines  to  create  more  efficient  index  estimates.  Hence,  in  practice  the  choice 
of  products  sampled  departs  significantly  from  strict  probability  sampling 
procedures. 
Finally,  although  the  BL!I  manuals  emphasize  that  transactions  rather  than 
list  prices  are  desired,  and  Form 473P  states  clearly  that  “net  transactions 
prices  are  the  most  desirable  type  of  price,*  the  BL!l  also  accepts  net  list AUDITING  THE  PRODUCER  PRICE  INDEX  -  Page  7  - 
prices  (with  additional  pricing  terms  listed  separately,  such  as  discounts  for 
prompt  payment),  or  other  estimates  of  prices.  Despite  the  BIS  emphasir  on 
transactions  prices,  our  discussions  with  personnel  at  various  pharmaceutical 
firms  suggest  that  firms  typically  interpret  this  request  as  being  one  for  net 
list  rather  than  net  transactions  prices. 
For  our  purposes  it  is  important  to  note  that  once  detafled  products  have 
been  chosen  by  the  disaggregation  process,  the  BIS  obtains  a  time-series  of 
prices  for  highly  defined  products  vhich  stays  constant  over  fairly  long 
intervals  - -  indeed,  the  six  years  betveen  re-sampling  suggests  that  the  set  of 
sampled  commodities  is  dominated  by  mature,  rather  than  innovative  products. 
As  was  noted  earlier,  the  most  recent  detailed  survey  in  pharmaceuticals 
occurred  in  mid-1987,  and  beginning  in  December  1987,  the  PPI  was  revised  to 
reflect  the  nev  sample  of  products,  within-cell  weights,  and  between-cell 
weights  from  the  1982  Census  of  Manufacturers.  Currently,  PPI’s  for 
pharmaceutical  products  are  based  at  100  in  June  1981. 
Although  in  principle  the  PPI  has  been  based  on  probability  sampling  since 
late  1978,  in  practice  it  is  clear  that  a  number  of  departuree  from  fdeal 
establishment  selection  and  disaggregation  occur.  In  addition  to  the  judgmental 
manner  in  vhich  the  number  of  price  quotes  per  establishment  is  determined,  the 
voluntary  nature  of  the  PPI  introduces  problems  for  BL8  field  representatives. 
Horeover,  the  U.  S.  Department  of  Labor  [1986a,1989]  data  collection  manuals 
provide  extensive  advice  to  BLS  field  representatives  when  the  establishment 
employee  interviewed  by  Bl.S  personnel  say  not  have  or  may  refuse  to  provide 
sufficient  information  for  complete  disaggregation.  Of  course,  the  implication8 
of  such  departures  of  practice  from  theory  are  not  clear. AUDITING  THE  PRODUCER  PRICE  INDEX  -  Page  8  - 
111.  mSeTSVSeb1 
Uo  now  dove  on  to  a  discussion  of  the  vatiour  data  nets  used  in  our 
analyris.  Confidential  data  have  baen  provided  us  by  four  of  the  ten  largest 
firms  in  the  industry,  together  comprising  about  24%  of  domestic  sales  in  1989. 
For  each  of  tha  2,090  ptorctiption  pharmaceutical  products  ptoducad  by  these 
four  coapanior,  ve  have  born  supplied  stonthly  data  from  January  1984  through 
December  1989  (72  monthly  observations)  on  net  tevenues,  quantity  shipped,  net 
tovenue/quantity,  snd  product  identifiera.  Net  tevenues  are  close  to  accrual 
basis,  implying  that  the  computed  svetago  ttenssctions  prices  are  close  to  the 
true  quantity-veiahted  l vetage  pricer  for  #ales  in  the  given  month.  Hovevet,  it 
is  worth  notin&  that  such  average  transactions  prices  could  in  principle  be 
affected  by  the  rite  and  location  of  transactions,  and  that  no  information  is 
l vsilable  to  us  on  vhethet  ruch  features  of  ttanractionr  have  changed  over  time. 
The  product  identifiers  sllov  unchanged  products  (down  to  the  presentation 
level)  to  be  followed  over  time,  since  presentation  characteristics  such  as  form 
(vial,  capsule),  dosage,  package  size  (count)  and  type  (bottle,  blister  pack) 
are  knovn. 
Since  none  of  the  companies  had  complete  records  of  forms  it  had  filled 
out  for  the  BLS,  in  response  to  vritten  requests  from  the  individual  companies, 
the  BLS  provided  a  computer  data  file  to  each  company  containing  records  of 
price  quotes  reported  by  that  company  to  the  BLS  from  January  1984  through 
December  1989.  The  companies  then  supplied  these  files  to  us.  The  sample  frame 
items  selected  by  the  BLS  represented  roughly  10-11X  of  the  four  companies’ 
total  revenues  in  both  cycles. 
Additional  product  details  vere  provided  us  by  each  company,  and  these 
vere  used  to  classify  products  into  therapeutic  classes  as  defined  by  the  BLS. 
Of  the  2,551  products  supplied  overall,  we  succeeded  in  classifyfng  81.9X  of AUDITING  THE  PRODUCER  PRICE  INDEX  -  Page  9  - 
them  into  specific  BLS  prescription  cell  groups  (see  Table  1  for  a  list  of  these 
cells)  ;  these  successfully  classified  products  accounted  for  aore  than  98%  of 
revenues  over  the  sample  period.’  In  this  paper,  when  VI  present  price  index 
data,  we  refer  to  calculations  based  on  tha  2,090  classifiad  prescription 
products  only. 
New  products  are  of  particular  interest,  for  they  may  embody  technological 
innovations  which  allow  therapeutic  actions  for  which  there  is  no  known  price, 
and  the  speed  vith  vhich  these  nev  products  are  introduced  into  price  index 
calculations  can  substantially  affect  the  measured  overall  rate  of  price  growth. 
Many  of  the  nev  products  in  the  companies’  data  sets  are  actually  modifications 
of  exlstlng  product  lines  (new  packaging.  etc.),  but  other  products  are  truly 
nev  in  the  sense  of  being  the  first  presentation  of  a  newly  approved  drug.  We 
have  also  examined  products  that  exit.  The  extremely  small  revenue  share  of 
exiting  products  makes  it  improbable  for  them  to  have  a  substantial  impact  on 
aggregate  measures  of  price,  and  therefore  we  do  not  explore  exits  in  detail  in 
this  study. 
It  is  of  course  quite  possible  that,  within  therapeutic  classes,  our  4- 
company  sample  of  firms  is  unrepresentative  of  the  industry  as  a  vhole.  TO 
assess  this  iss.ue  for  one  important  class  of  drugs,  we  have  obtained  monthly 
price  and  revenue  data  on  almost  the  entire  universe  of  products  within  systemic 
anti-infectives  (SIC  2834-111).  a  sub-class  accounting  for  approximately  16X  of 
SIC  28341  domestic  total  sales  in  1987.  The  data  were  purchased  from  MS 
America.’  The  number  of  products  for  which  IHS  monthly  price  data  is  available 
is  5,545,  but  the  IHS  time  period  differs  slightly  from  that  for  our  four 
companies  --  from  October  1984  rather  than  January  1984  to  December  1989. 
There  are  several  other  important  differences  between  the  company-specific 
and  IHS  data.  lo  Uhile  the  data  underlying  the  PPI  are  those  on  prices  received 
by  producers  from  whomever  makes  the  first  purchase,  the  IHS  data  cover AUDITING  THE  PRODUCER  PRICE  INDEX  -  Pago  10  - 
transactions  at  a  different  point  in  tha  distribution  chain.  Specifically,  the 
MS  data  roprosent  tha  purchases  made by  hospitals  and  by  retailers  of  ethical, 
l thical  over-the-counter,  and  proprietary  pharmacautical  producta.  IHS 
estimator  that  its  drugstore  audit  covars  67X  of  the  US pharmaceutical  market, 
and  that  its  hospital  audit  covers  an  additional  16X.  The  market  segments  that 
the  two  audits  do  not  monitor  include  foodrtores,  dispensing  physicians,  IWO’s, 
aail  order  nursing  homes,  and  clinics. 
Tha  purchase  information  obtained  by  INS  from  a  panel  of  hospitals  and  a 
sample  of  wholesale  varehouses  for  its  hospital  audit  is  projected  by  ItlS  to 
national  (continental  US)  levels,  not  including  federal  horpitals  or  nursing 
homes.  Based  on  invoice  data,  the  prices  reflect  the  actual  costs  of  products 
to  hospitals,  vhether  purchased  from  a  manufacturer  or  a  vholeoaler.  11 
In  the  retail  data  set,  invoice-based  price  data  reflect  the  actual  cost 
to  retailers  for  the  ethical,  ethical  over-the-counter  and  proprietary 
pharmaceutical  products,  vhether  purchased  from  a  manufacturer  or  a  wholesaler 
(ItiS  notes  that  92X  of  total  pharmaceuticals  purchased  by  ratail  outlets  are 
from  vholesalers).  For  both  the  hospital  and  retail  data,  IUS  cautions  that 
prompt  payment  cash  discounts  (usually  2X  off)  and  bottomline  invoice  discounts 
are  not  reflected  in  the  dollar  purchase  amounts. 
1II.a  PRICE  INDEXES DISAGGREGATED  BY  PRODUCT  CUSS 
Because  the  PPI  and  IHS  data  are  taken  from  different  points  in  the 
distribution  chain,  the  prlccs  (unit  costs)  in  the  IMS  data  reflect  markups  over 
the  prices  reported  by  producers  to  the  BLS.  These  markups  could  vary  over 
time,  or  be  trended.  To  check  on  the  possibility  that  IHS  prices  grov 
differently  from  producer  prices,  ve  have  compared  prices  for  241  exact  product 
matches  between  IHS  and  the  four-company  data.  l2  Specifically,  for  each  of 
these  241  products,  ve  have  taken  the  ratio  of  the  1%  unit  cost  to  the 
company’s  average  revenue,  monthly  from  October  1984  through  December  1990.  We AUDITING  THE  PRODUCER  PRICE  INDEX  -  Page  11  - 
then  computed  a  Divisia  index  of  this  ratio,  using  company  revenue  weights.  If 
the  markups  were  constant  over  time,  growth  of  this  Divisia  index  would  be  zero. 
Over  the  October  1984-December  1990  time  period,  this  index  grew  from  1.000  to 
1.041,  an  average  annual  grovth  rate  (MGR)  of  0.77X,  implying  that  IHS  prices 
grev  slightly  more  than  company-specific  average  revenues  for  these  241 
products.  l3  We  interpret  this  result  as  implying  that  even  though  IHS  and  PPI 
prices  are  dravn  Cram  different  points  in  the  distribution  chain,  on  average 
their  price  changes  are  similar  over  the  sample  time  period.  This  similarity  in 
overall  growth  rates  of  the  IHS  and  company-provided  data  also  gives  us  some 
confidence  in  using  the  INS  data  as  a  proxy  for  producer  price  level  price  index 
calculations.  14 
Using  this  XHS  data,  we  have  computed  alternative  price  indexes  for  the 
systemic  anti-infectives  sub-class  (recall  that  the  IHS  data  encompass  almost 
the  universe  of  products  sold  domestically).  Our  results  are  summarized  in 
Figure  2.  Over  the  October  1984  through  December  1989  time  period,  while  the 
(Insert  Figure  2  somevhere  near  here) 
official  BLS  PPI  for  systemic  anti-infectives  increased  at  an  MCR  of  6.261,  the 
IHS  Laspeyres  fixed-weight  index  grew  at  2.633,  and  the  INS  Divisia  index  with 
new  goods  included  immediately  grew  at  only  1.54%  --  one  fourth  the  growth  rate 
of  the  official  PPI .I5  Hence,  there  is  indeed  a  mystery  here,  for  vhen  data  are 
taken  from  a  product  class  vith  almost  universal  coverage,  the  official  PPI  and 
the  IHS-based  Laspeyres  and  Divisia  indexes  grov  at  very  different  rates.  Hence 
it  appears  that  our  initial  findings  based  on  all  products  from  but  four  firms 
are  corroborated  using  the  universe  of  products  for  the  systemic  anti-infective 
subclass. 
Some  other  evidence  can  shed  light  on  the  representativeness  of  our  four- 
company  sample  and,  in  particular  on  the  possibility  that  product  mix 
differentials  along  with  variations  in  price  growth  by  product  sub-class  could 0 
Index  Value 
-0 
v  m  e 
.  . 
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Table  2 
FOUR  COHPANY  AND  INDUSTRY  DATA 
Product  Share 
Product  Distribution 
Product  Class  L&IR 
Class  4 -Company 
Nmbe t  l9.z 
Analgesics  102 
Anti-erthritics  LO5 
Anti-coagulents  LO6 
Systemic  Anti-infectives  111 
Anti-spasmodic/ 
Anti-secretory  116 
Cancer  therapy  119 
Cardiovascular  121 
Cough  b  Cold  Preparations  125 
Dermatological 
Preparations  126 
Diabetes  Therapy  127 
0.65  2.94 
17.44  19.60 
0.02  1.67 
0.56  3.48 
9.34  2.89 
Hormones  135  2.56  4.50 
Hustle  Relaxants  139  1.83  1.79 
Nutrients  6  Supplements  141  0.08  2.30 
Psychotherapeutics  144  9.05  8.27 
Sedatives  145  2.76  1.10 
All  Others  10.86  14.39 
TOTAL  100.00  100.00  100.00  100.00  24.16 
3.59%  7.22%  5.21X  9.82X  12.011 
13.36  6.21  3.41  4.83  51.92 
0.14  0.59  0.51  0.68  5.84 




Census  -  BLS  Approximate 
Relative  Four-Company 
Weights  Concentration 
l2zcLeaz 
1.70  1.01 
1.12  3.77 
10.26  15.64 
2.04  3.60 
2.60  3.37 
2.49  1.97 
10.92  3.78 
1.71  0.86 
0.23  0.24 
10.95  7.57 
1.18  0.80 
31.44  26.78 












Notes:  The  l-company  product  share  distribution  is  total  revenues  for  the  four 
companies  by  product  class,  divided  by  the  sum of  the  four  companies'  total 
prescription  classified  revenues  (total  1987  revenue  less  non-prescription 
assignments  Less  unassigned  revenues).  The  MS-All  product  shore  distribution  fr 
total  industry  revenues  by  product  class  divided  by  the  sum of  total  revenues 
across  all  firms  in  the  industry.  The  Census-BLS  weights  are  the  relative  value 
of  shipments  net  of  intraindustry  sales  by  product  class,  based  on  the  1977  and 
1982  Census.  The  4-company  concentration  ratio  is  company-provided  data  on  total 
revenues  for  the  four  firms  in  this  study  by  product  class,  divided  by  IHS 
estimated  total  industry  revenues  by  product  class.  Since  the  IHS  data  include 
wholesaler  markups,  this  4-company  concentratfon  ratio  slightly  understates  the 
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account  for  differences  In  four-company  price  growth  vs.  that  of  the  official 
PPI.  Based  on  revenue  data  from  the  four-company  rample,  we  have  computed 
product  revenue  share  data  by  product  class,  and  compared  these  to  Industry-wide 
product  distribution  data  estimated  by  IHS.16  The  two  sets  of  product 
dIrtrIbutIon  shares  are  given  In  Table  2.  There  It  Is  seen  that  product 
distribution  shares  differ  somewhat  betveen  our  four-company  sample  and  the  ItlS 
.unIverse.. 
We  have  also  obtained  Census  Bureau  data  on  revenues  by  product  class 
based  on  the  1977  and  1982  Census  of  Hanufacturer.  As  Is  aeen  In  Table  2,  the 
1982  Census-BLS  veights  are  broadly  consistent  with  the  product  share  data 
reported  by  IHS  for  1987,  although  by  1987  the  vefghtr  of  anti-spasmodic/anti- 
secretory,  cardiovascular,  and  nutrients  6  supplements  vere  larger  than  In  1982, 
vhile  that  for  analgesics  vas  somevhat  smaller. 
In  Table  3,  we  report  MCR  of  the  published  PPI,  the  four-company 
Laspeyres,  and  the  four-company  DIvIsIa  index,  by  product  class,  over  the  l/84  - 
12/89  time  period.  The  Laspeyres  Index  mimickr  the  BL.S  fixed  veight  vith  splice 
computational  procedures,  vhereas  the  Divisia  Index  Includes  nev  goodr 
Immediately  and  employs  smoothed  four-month  moving  average  share  veights.“l  As 
IO  seen  In  Table  3,  In  most  cases  the  PPI  grovth  Is  larger  than  that  for  the 
four-company  DIvIsIa  (especially  for  cancer  therapy  products,  dermatological 
preparations,  and  sedatives),  but  in  some  cases  the  PPI  grows  less  rapidly  than 
the  four-company  Divisia  (for  example,  In  anti-arthritics,  and  especially  in 
muscle  relaxants).  We  conclude,  therefore,  that  while  on  average  the  PPI  for 
pharmaceutical  preparations  grows  considerably  more  rapidly  than  the  four- 
company  Divisia  (9.09X  vs.  6.03X),  there  1s  considerable  diversity  across  sub- 
classes  and  In  some  cases  the  Inequality  is  reversed. AUDITING  THE  PRODUCER  PRICE  INDEX  -  Page  14  - 
Table  3 
GROWTH  IN  ALTERNATIVE  PRICE  INDEXES  BY  DISACCRECATED  PRODUCT  CUSS 
AAGR  of  Price  Indexer  l/84  thru  12/89 




Systemic  Anti-infectives 
Anti-spasmodic/ 
Anti-secretory 
Cancer  therapy 
Cardiovascular 
Cough  6  Cold  Preparations 
Deroatological 
Preparations 
Diabetes  Therapy 
Hormones 
Hustle  Relaxants 




Product  Official  PPI 








116  na  3.01  5.51 
119  12.66  -2.01  -0.17 
121  10.49  10.54  8.16 
125  0.75  7.24  7.15 
126  12.76  6.53  5.80 
127  na  4.64  3.99 
135  5.12  4.31  2.24 
139  10.92  12.96  22.63 
141  8.75  4.77  4.59 
144  14.04  13.02  9.76 




9.55%  8.63% 
5.52  5.68 
1.59  4.50 
2.21  1.20 
6.68 
Total  Using  1977  Census  Ueighta  7.06  5.81 




Note:  na  implies  that  the  PPI  for  this  industry  is  not  published,  due  to  an 
insufficient  number  of  reportings  to  the  BLS. 
As  another  check  on  the  persistence  of  our  mystery  and  the  representative- 
ness  of  our  four-firm  sample,  we  have  used  item-specific  veights  to  compute  MCB 
by  industry  sub-class  (see  the  last  two  columns  of  Table  3).  but  have  then 
constructed  an  overall  price  index  weighting  these  sub-classes  using  the  BLS- 
Census  weights  from  Table  2,  rather  than  the  four-company  veights.  If  the 
revenue  distribution  across  product  classes  in  our  four  COmpanieS  Vera 
sufftciently  different  from  the  BLS-Census  weights,  then  the  MCR  for  SIC  28341 AUDITING  THE  PRODUCER  PRICE  INDEX  -  Page  15  - 
in  total  could  differ  depending  on  whet  weights  were  employed.  As  is  seen  in 
the  last  three  rows  of  Table  3,  however,  this  is  not  the  case.  Using  four- 
company  sub-class  weights,  we  see  that  the  AAGR  of  the  Laspeyres  index  is  6.681, 
while  those  based  on  the  1977  and  1982  Census  weights  are  7.06X  and  6.971, 
respectively;  for  the  Divisia  index,  the  four-company  weights  yield  an  MCR  of 
6.03Z,  while  use  of  the  1977  or  1982  Cetuua  veights  generates  MCR’s  of  S.BlZ 
and  5.871.  Since  these  differences  are  minor  compared  to  the  much  larger  MGR 
of  the  official  PPX  (9.09X),  we  conclude  that  variations  in  revenue  product 
class  weights  between  our  four  companier  and  the  industry  overall  cannot  account 
for  the  discrepancy  between  growth  of  the  official  PPI  and  various  price  indexes 
based  on  our  four-company  data. 
I1I.b  REPORTED  VS.  ACTUAL  AVERAGE  TRANSACTIONS  PRICES 
As  another  aspect  of  our  data,  we  have  compared  prices  reported  to  the  BLS 
by  the  four  companies  with  average  transactions  prices  received  by  the  company. 
For  the  25  products  sampled  in  Cycle  I  and  for  the  46  items  sampled  in  Cycle  II 
from  the  four  companies  (7  are  retained  from  Cycle  I  to  Cycle  II,  leaving  a 
total  of  64  products)  the  Laspeyres  index  of  prices  reported  to  the  BLS 
increased  at  an  MCR  of  8.94%,  while  average  transactions  prices  increased  at 
9.52X  per  year.lg  Thus  the  8.94%  MCR  of  prices  reported  to  the  BLS  by  our  four 
companies  is  almost  identical  to  the  9.09X  MGR  of  the  PPI,  suggesting  that  In 
terms  of  price  growth  for  sampled  items,  our  four  companies  are  essentially 
representative  of  the  industry  as  a  whole. 
We  have  also  compared  reported  prices  and  average  transactions  prices  for 
the  sampled  items  in  the  systemic  anti-infectives  product  sub-class.  Over  the 
entire  l/84-12/89  time  span  the  two  Laspeyres  indexes  grew  at  virtually 
identical  rates  --  8.60X  for  transactions  prices,  and  8.53%  for  reported  prices, AUDITING  THE  PRODUCER  PRICE  INDEX  -  Page  16  - 
both  of  which  are  considerably  larger  than  the  official  PPI  which  grew  at  an 
AAGR  of  6.22X?’ 
Reported  and  average  transactions  prices  can  also  be  compared  in  terms  of 
levels  rather  than  growth  rates.  For  the  same four-company  sample,  the 
unveighted  average  of  the  ratio  of  reported  to  average  transaction  price  vas 
1.090.  while  a  corresponding  revenue-veighted  ratio  is  1.032;  it  is  worth 
noting,  however,  that  these  ratios  display  considerabla  variability. 
IV.  SOME CLUES AND AN IMPORTANT m 
Our  analysis  to  this  point  suggests  that  the  products  sampled  by  the  BLS 
in  this  industry  appear  to  have  price  trends  that  differ  from  representative 
transactions  for  the  four  companies  in  our  sample,  and  in  the  systemic  anti- 
infective  sub-class,  from  essentially  the  industry  as  a  whole.  What  is  it  about 
the  BLS  sampling  procedures  that  on  average  appear  to  miss  the  smaller  price 
increases  of  representative  transactions? 
Since  the  potential  existence  of  a  ‘new  goods”  problem  has  been  known  for 
quite  some time,  2o  ve  began  our  search  for  an  explanation  by  simply  looking  at 
the  mean age  of  products  sampled  by  the  BLS  relative  to  the  average  age  of  all 
dated  products  in  the  four  companies.21  This  coarse  analysis  turned  out  to  be 
uninformative,  since  differences  vere  small. 
Another  line  we pursued,  followlng  a  conjecture  presented  in  Berndt, 
Criliches  and  Rosett  (19901,  involved  examining  the  extent  to  which  items 
sampled  by  the  BLS  in  Cycle  I  were  re-sampled  by  them  in  Cycle  II.  For  the  25 
items  in  the  four  companies  sampled  by  the  BLS  in  Cycle  I,  seven  were  re-sampled 
in  Cycle  II.  Whether  such  a  28~  re-sampling  rate  is  consistent  with  probability 
sampling  procedures  is  not  clear,  but  it  appears  unlikely  to  us  that  this  amount 
of  re-sampling  could  be  responsible  for  the  BLS  sample  failing  to  pick  up 
adequately  the  smaller  price  increases  of  representative  transactions. AUDITING  THE  PRODUCER  PRICE  INDW  -  Page  17  - 
Uo  then  examined  the  role  of  new products  in  a  different  manner, 
conjecturing  that  while  the  distribution  of  products  by  age  may  p11 sveragg  be 
roughly  l imilar  for  the  BLS  sampled  items  and  the  four-company  aggregate,  they 
might  be  skewed  in  different  ways.  To  follov  this  up,  we  first  defined  six  age 
groups  (leee  than  two  years  old,  between  2  and  3.999  years,  4  and  6.999  years,  7 
and  9.999  years,  10  and  24.999  years,  and  25  or  more  years  old).  We  then  divide 
age  group  specific  revenues  of  BLS  sampled  items  in  the  four  companies  by  total 
annual  revenues  for  all  BLS  sampled  items  at  the  four  companies.  Similarly, 
four-company  l ge-specific  revenue  sharer  vere  defined  as  the  aggregate  annual 
age-group  l pacific  revenues  for  the  four  companies  divided  by  total  annual 
revenues  for  the  four  companies.  As  is  seen  in  Table  4,  the  results  of  these 
calculations  begin  to  provide  important  clues  to  help  unravel  our  mystery. 
Table  4 
Annual  Revenue  Shares  by  Age  of  Product  for  Items  at  the  Four  Companies 
Sampled  by  the  BIS,  and  for  All  Products  at  the  Four  Companies 
CYCLE  I  TIME  PERIOD  CYCLE  11  TIME  PERIOD 
Universe  Sample 
Aire  in  Years  lj&  M 
0  -  1.999  20.78%  0.00% 
2  -  3.999  16.70  8.96 
4  -  6.999  17.40  13.13 
7  -  9.999  11.73  30.24  10.01  28.72  18.79  39.19  19.14  44.56 
10  -  24.999  23.43  45.18  15.92  30.21  16.92  13.32  13.43  10.05 
,25  or  more  9.96  2.50  5.75  2.00  4.69  1.69  3.07  1.41 
TOTAL  100.00  100.01  100.00  100.00  100.00  100.00  100.00  100.01 
Universe  Sample 
l!az  l%!z 
32.57%  0.00% 
14.81  9.08  8.62  4.02  7.16  3.28 
20.94  29.99  29.13  33.20  28.11  33.39 
Universe  Sample 
lm  leaa 
21.85%  8.58% 
Universe  Sample 
1989 
26.29%  7.32% 
Notes:  The  age  in  years  for  Cycle  I  is  as  of  January  1,  1984,  and  that  for  Cycle 
II  is  January  1,  1988.  Totals  may  not  sum  to  100%  due  to  rounding. AUDITING  THE  PRODUCER  PRICE  INDEX  -  Page  18  - 
In  1984  and  1987,  while  items  under  two  years  of  age  were  not  sampled  at 
all  by  the  BLS  (recall  that  the  Cycle  I  survey  occuted  in  June  1981),  products 
less  than  two  years  comprised  about  21%  (1984)  to  33%  (1987)  of  total  sales  at 
the  four  companies;  products  between  two  and  four  years  old  comprised  about  17X 
(1984)  or  1X  (1987)  of  company  total  sales,  while  BLS  sampled  items  within  this 
age  group  constituted  about  9X  of  revenues  in  both  1984  and  1987.  Al  toga  ther 
for  both  age  groups,  shares  of  BL!I  sampled  products  under  four  years  of  age 
generated  only  9X  of  revenues,  while  at  the  four  companies  these  products 
constituted  between  38%  (1984)  and  47X  (1987)  of  total  sales.  Hence.  younger 
products  appear  to  be  undersampled  by  the  BLS. 
Relative  to  company-wide  shares,  during  both  cycles  the  BLS  over-sampled 
medium-aged  products,  especially  in  the  7-10  age  group.  For  example,  as  is  seen 
ln  Table  4,  BLS  sampled  products  between  7  and  10  years  of  age  accounted  for 
about  30X  of  1984  BL!I  item  revenues,  but  this  age  group  generated  only  12X  of 
total  company  revenues;  in  1989,  the  corresponding  shares  are  45%  and  19%. 
Recall  that  earlier  we  reported  that  sales-weighted  mean  ages  for  BLS 
sampled  items  and  the  universe  of  the  four-company  items  vere  very  similar.  In 
this  context,  it  is  vorth  noting  that  the  age  distribution  of  products  sampled 
by  the  BLS  tends  to  be  much  more  concentrated  than  is  that  for  all  products  at 
the  four  companies.  In  1989,  for  example.  products  between  ages  4  and  10 
comprised  about  78%  of  BLS  sampled  item  revenues,  yet  only  accounted  for  about 
47%  of  four-company  revenues, 
While  these  substantial  differences  in  shares  by  age  group  are  striking, 
they  would  not  contribute  at  all  to  unravelling  our  mystery  were  it  the  case 
that  product  price  changes  by  age  group  are  similar.  If,  however,  for  whatever 
reason,  younger  products  that  are  undersampled  by  the  BLS  experience  lees  than 
average  price  increases  while  medium-aged,  oversampled  items  undergo  larger AUDITING  THE  PRODUCER  PRICE  INDEX  -  Page  19  - 
price  increases,  then  we  would  be  able  to  understand  better  why  the  MGR  of  the 
four-company  universe  and  the  PPI  differ. 
To  check  on  thia  further,  we  ran  a  regression  based  on  5,761  observations 
from  our  four-company  sample.  Specifically,  we  first  computed  an  annual  average 
transactions  price  for  each  product  as  total  annual  revenues  divided  by  total 
annual  quantity.  We  then  defined  an  annual  price  change  dependent  variable 
d  log  P  as  the  logarithmic  first  differences  of  these  prices.  AS  regressors,  we 
l ptcifitd  dummy  variables  for  the  age  of  the  product  for  the  six  age  classes 
noted  above  (using  the  age  of  the  product  as  of  December  31  of  the  latter  year), 
company  dummies,  year  dummies,  and  SIC  product  class  dummies.  The  rtsultt  of 
this  regression,  with  observations  weighted  by  revenue  shares  22  ,  art  presented 
ln  Table  5.  Note  that  the  year  dummies  refer  to  differences  in  the  rate  of 
change  from  that  occurring  bttvttn  1984  and  1985;  the  age  dummies  are 
interpreted  as  differences  in  the  rate  of  price  growth  froa  that  for  the  over 
age  25  product  group. 
At  is  teen  in  Column  (1)  of  Table  5,  relative  to  the  over  age  25  product 
group,  items  less  than  two  years  old  experience  about  a  3.5%  smaller  annual 
price  change,  vhilt  items  between  7  and  10  years  old  experience  about  a  2.5X 
larger  annual  price  change,  uttrls  Daribug:  the  t-value  of  greater  than  six  for 
each  of  these  two  coefficients  indicates  strong  statistical  significance. 
Products  between  2  and  4  and  between  4  and  7  years  old  have  slightly  smaller 
price  changes,  but  the  t-values  of  less  than  one  suggest  that  items  from  these 
age  groups  do  not  experience  statistically  significantly  different  price 
changes.  Finally,  products  in  the  lo-25  age  group  (which  includes  in  particular 
patent  expired  products)  experience  about  a  0.8%  larger  annual  price  change 
relative  to  over  age  25  products,  but  the  1.779  t-value  implies  statistical 
stgnfffcance  only  at  levels  less  than  about  92.5%. AUDITING  TNE  PRODUCER  PRICE  INDEX  -  Page  20  - 





































AGE(  7<10)  .0250 
(6.10) 
ACE(lO<25)  .0031 
(0.67) 
BLSDUMKY  . .  .0292 
(6.61) 
SIC  2834111  Only 
(3)  (4) 
-.0321  -.0376 
(2.33)  (2.74) 
-.0003  .OOOl 
(0.02)  (0.01) 
.0017  .0028 
(0.12)  (0.21) 
-.0564  -.0584 
(4.18)  (4.37) 
. .0349  -.0308 
(2.42)  (2.15) 
-0212  .0196 
(1.25)  (1.16) 
- .0399  -.0401 
(2.91)  (2.94) 
.0311  .0256 
(2.43)  (2.01) 
.0830  .0728 
(5.87)  (5.13) 
.0844  .0744 
(6.24)  (5.48) 
.0560 
(4.66) 
R2  .1632  .1695  .1746  .1901 
N  5761  5761  1147  1147 
Table  5 
Results  from  Revenue  Weighted  Ago-Price  Regressions 
d  log  P  as  Dependent  Variable 
(Absolute  value  of  t-statistics  in  parentheses) 
All  Products 
(1)  (2) 
Note:  Regressions  also  included  company  dummies,  and  in  the  case  of  the 
all  products  regressions,  SIC  sub-class  dummies. 
We also  ran  a  regression  identical  to  (1)  but  with  a  dummy  variable  equal 
to  one  if  the  item  were  sampled  by  the  8l-S  in  the  latter  year;  results  ere AUDITING  THE  PRODUCER  PRICE  INDEX  -  Page  21  - 
given  in  Column  (2)  of  Table  5.  The  estimated  coefficient  on  BLSDUHMY  variable 
is  .0292,  vlth  a  t-value  of  6.61,  indicating  that  on  average,  items  sampled  by 
the  BLS grev  et  an  almost  3% larger  MGR  than  other  items.  Notice  that  this 
2.92%  coefficient  is  almost  as  large  as  the  3.06%  difference  between  the  grovth 
rate  of  the  official  PPI  for  SIC  28341  (9.09X)  and  that  for  the  Divisia  index 
of  our  four-company  sample  (6.03%).  The  comparison  with  the  Divisla  index  1s 
appropriate  here,  for  the  dependent  variable  in  these  regressions  are 
constructed  similar  to  the  price  rel@cives  of  the  Divfsia  index. 
For  our  purposes,  it  is  important  to  note  that  the  tvo  clearly 
signiffcant  age-related  coefficients  from  the  age-price  regressions  (1)  and  (2) 
of  Table  5  coincide  vfth  the  tvo  age  groups  vhere  the  BLS sample  and  four- 
company  universe  revenue  shares  differ  most  dramatically  --  under  age  tvo  and 
betveen  ages  7  and  10  (see  Table  4).  Thus  there  is  clear  evidence  supporting 
the  notion  that,  vith  respect  to  age,  items  undersampled  by  the  BLS experience 
belov-average  price  changes,  while  items  oversampled  by  the  BLS undergo  above- 
average  price  changes. 
To  quantify  the  implications  of  this  combined  unrepresentative  sampling  - 
differential  price  change  by  age  group  phenomenon in  unraveling  our  mystery  in 
an  l ltern8tive  manner,  we have  constructed  a  simple  accounting  relationship. 
Let  us  predict  total  price  grovth  as  a  function  of  revenue  shares  and  age- 
specific  price  grovth,  separately  for  the  items  sampled  by  the  BLS, 
i  5 
3 
‘BLS - i~lvi,*Ls  iy  ’  [  I 
and  for  the  four  companles, 
i,  b  Gli  - i~lvt,coH  6  ’  [ 1 
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where  the  Pi/Pi  are  approximated  by  the  regression  coefficients  from  Table  ‘5. 
Then  subtract  (2)  from  (l),  impose  the  condition  that  the  vi,Bu  and  the  vi,Cw 
weights  each  sum  to  unity  over  the  six  age-groups,  and  collect  terms.  ThfS 
yields  the  expression 
E  -1 
pBLS  %lH-  iil(  ii ;6 
“i,BLs  -  “i,cod  q  -  5  1  1 
(3) 
where  the  6  subscript  refers  to  the  sixth  age  group  (products  over  age  25). 
According  to  (3).  the  difference  in  predicted  growth  rates  between  the  BLS  and 
the  four-company  (COH)  aggregate  price  indexes  depends  on  corresponding 
differences  in  the  vi  share  vtights  times  any  difftrtnctt  in  price  changes  by 
age  group. 
To  set  hov  this  relationship  helps  to  understtnd  the  difference  between 
AAGR’t  of  aggregate  sampled  and  four-company  universe  price  indexes,  vt  employ 
the  Table  4  entries  to  compute  differences  in  shtre  vtfghtt,  and  the  parameter 
tstimattt  of  Columnn  (1)  in  Table  5  to  approximate  the  difftrtntlals  in  price 
grovth  by  age  group.  Specifically,  to  reflect  the  BLS  fixed  veights  within 
Cycles  I  and  II,  ve  use  as  estimates  of  the  vi,BM  weights  the  arithmetic  mans 
of  the  1984  and  1988  BLS  vtights  in  Table  4,  and  as  ettfmatts  of  the  vi,cm 
fixed  veights,  vt  use  the  arithmetic  mean  of  the  1984  and  1988  four-company 
universe  vtights.  Substituting  these  values  into  equation  (3),  and  noting  that 
the  aggregate  price  index  of  BLS  sampled  items  grew  at  an  MGR  of  8.94%  vhile 
that  for  the  universe  of  products  at  the  four  companies  grtv  at  an  MGR  of 
6.68X,  vt  find  that  of  the  2.26%  difference  in  AAGR’s  (8.94X  -  6.68%),  1.18X  it 
“explained”  by  the  right-hand  side  of  equation  (3)  --  differences  in  share 
veights  times  differentials  in  rates  of  price  change  by  age  group. 
This  is  a  rather  satisfying  finding,  for  it  implies  that  if  one  confines 
the  analysis  to  differences  bttvetn  tvo  Laspeyrts-type  indexes,  this  very AUDITING  THE  PRODUCER  PRICE  INDEX  -  Paga  23  - 
simple  accounting  rtlationahip  can  explain  approximately  52% (1.18X/2.26%)  of 
the  difference  in  MCR  as being  due  to  the  BLS ovtrsampling  products  uith 
above-average  price  increases  and  undersampling  of  items  with  below-average 
price  changes.  23 
We have  also  undertaken  a  similar  analysis  for  the  systemic  anti- 
infactives  sub-class  of  products.  The  regression  equation  we  estimated  is 
given  in  Column  (3)  of  Table  5.  As  is  seen  there.  stttr&ribup,  products 
between  7  and  10,  and  between  10  and  25  ytara  experience  particularly  large 
price  increases,  while  young  products  undergo  much smaller  price  changes. 
Further,  when a  BLS  sampled  item  dummy  variable  was  added  to  thts  equation  (see 
Column  4  of  Tsblt  5),  the  estimated  coefficient  on  the  BIS  dummy variable  is 
.OS60,  vith  a  t-value  of  4.66.  Hence,  other  things  equal.  for  ayattmic  anti- 
inftctivta,  on  average  items  sampled  by  the  BLS  grtv  at  an  MCR  of  about  5.8% 
higher  than  all  other  items.  Moreover.  of  the  6.28%  difference  in  MCR  between 
BlS  aampltd  (8.53X)  and  four-company  universe  (2.25%)  items,  2.70%  is 
‘explained”  by  the  right-hand  aide  of  equation  (4);  hence  about  43X  (2.70/6.28) 
of  the  discrepancy  can  be  explained  by  differences  in  share  weights  and 
differentials  in  rates  of  price  change  by  age  group.  For  Cycle  I,  this 
proportion  is  36X  (1.89/5.27),  while  for  Cycle  II  it  is  38% (3.26/8.54). 
It  is  vorth  emphasizing,  however,  that  in  this  paper  vt  do  not  ask  vhy  it 
ia  that  the  BtS  oversamples  medium-age  products  and  undersamples  never 
products,  nor  do  ve  pursue  why  it  is  that  price  changes  for  medium-age  products 
tend  to  be  larger  than  those  for  younger  products. 
V.  YOUNG  c SING  WEI- 
Having  accounted  for  a  rubatantal  portion  of  the  difference  bttvttn  tvo 
Laapeyrea-type  indexes  on  the  basis  of  BLS non-representative  sampling,  ve  now 
turn  our  attention  briefly  to  an  examination  of  the  role  of  relatively  young AUDITING  THE  PRODUCER  PRICE  INDEX  -  Page  24  - 
goods  and  varying  share  veights  in  helping  to  understand  the  difference  between 
a  traditional  taspeyres  and  various  other  Laspeyres  and  Divisia  indexes. 
Recall  that  during  Cycle  I,  the  BLS  sample  frame  consisted  of  products 
chosen  in  1981,  and  that  this  set  of  sampled  items  remained  until  January  1988, 
vhen  the  nev  Cycle  II  sample  frame  vas  introduced.  Since  ve  do  not  knov  what 
the  1981  revenue  shares  vere,  in  attempting  to  miaick  the  BLS  procedures  using 
a  Laspeyres  price  index  we  have  employed  1984  fixed  quantity  weights  during 
Cycle  I.  and  1988  fixed  quantity  veights  during  Cycle  11.  This  implies  that 
goods  introduced  after  January  1984  but  vithin  Cycle  I  vere  excluded  until 
1988.  and  goods  introduced  after  January  1988  vere  excluded  from  Cycle  II. 
As  is  seen  in  Table  6,  vhen  this  “usual  Laspeyres”  procedure  ir  employed 
for  all  product  classes  in  our  four-company  data,  the  AAGR during  Cycle  I, 
Cycle  II  and  the  total  time  period  are  6.58X,  6.893,  and  6.68%.  respectively, 
while  the  corresponding  official  PPI  grev  at  9.20X,  8.85X  and  9.09%.  Had  the 
sample  frame  not  changed  in  January  1988,  had  the  quantity  veights  not  been 
altered  then,  and  thereby  had  all  products  introduced  after  January  1984  been 
completely  excluded,  the  Laspeyres  price  index  vould  haved  grown  at  an  AAGR  of 
9.692  instead  of  6.89X  during  Cycle  II,  and  7.58X  instead  of  6.68%  over  the 
entire  l/84-12/89  time  period.  Hence,  the  changing  of  the  sample  frame  in 
January  1988  had  a  substantial  impact  on  the  Laspeyres  index. 
With  the  Divista  index.  the  weights  assigned  to  each  product  differ  by 
month  reflecting  changing  product  market  shares,  and  new  goods  are  introduced 
immediately,  thereby  having  an  impact  on  the  overall  index.  To  consider  the 
impact  of  the  Cycle  II  sample  frame  change,  ve  computed  an  alternative  Divisia- 
type  aggregate  price  index  in  vhich  the  set  of  goods  during  the  Cycle  I  era 
consisted  only  of  those  present  in  January  1984,  and  the  set  of  goods  during 
Cycle  II  included  only  those  present  in  January  1988,  i.e.  nev  goods  were 
excluded  except  as  of  January  1988.  Results  from  this  calculation  are  also AUDITING  THE  PRODUCER  PRICE  INDEX  -  Page  25  - 
given  in  Table  6,  where  it  is  seen  that  allowing  revenue  share  weights  to 
change  but  restricting  the  set  of  products  to  incumbent  ones  except  for  a 
January  1988  update  results  in  growth  rates  surprisingly  similar  to  the 
traditional  Laspeyres  index  --  6.36%  vs.  6.58X  in  Cycle  I,  7.12X  vs.  6.89X 
during  Cycle  II,  and  6.61X  vs.  6.68X  overall.  However,  when  the  set  of 
products  used  excludes  all  nev  goods  (i.e.,  all  products  introduced  after 
Table  6 
MGR  of  Aggregate  Price  Indexes  vith  Alternative  Treatments  of  New Goods 
Official  PPI 
BLS  Sampled  Items  - 
Usual  Laspeyres 
Laspeyres-Usual 
All  items 
topeyres-Nev  goods 
completely  excluded 
Divisia-Nev  goods 
excluded  except 
update  at  l/gg 
Divisia-New  goods 
completely  excluded 
Divisia- 
Usual 
Cycle  I,  Cycle  11  Jnd  Overall 
All  Products 
Cycle  I  Cycle  II  Total 
-  2 
9.20x  8.8SX  9.09x 
-  any  Dau 
7.74  11.49  8.94 
6.58  6.89  6.68 
6.58  9.69  7.58 
6.36  7.12  6.61 
6.36  9.57  7.39 
5.43  7.31  6.03 
January  1984))  the  fixed-weight  Laspeyres  and  the  varying-veight  Divisia  yield 
more  discrepant  grovth  rates  --  6.58%  vs.  6.36X  in  Cycle  I,  9.69X  vs.  7.12X  in 
Cycle  II,  and  7.58%  vs.  6.61X  overall.  Finally,  vhen  nev  goods  are  introduced AUDITING’  THE  PRODUCER  PRICE  INDEX  -  Page  26  - 
into  the  Divisia  price  index  as  soon  as  is  feasible,  thr  MCR’s  fall 
considerably  - -  to  5.43%  in  Cycle  I,  7.30X  in  Cycle  II,  and  6.03X  oyerall.24 
We conclude,  therefore,  that  differences  in  MCRs  between  the  Lmpeyres 
and  Divisia  indexes  are  rather  modest,  provided  that  computations  are 
undertaken  over  an  identical  set  of  goods.  Hovever  ,  when  the  set  of  goods 
included  in  the  computations  incorporates  new  and  relatively  young  products 
immediately,  the  resulting  Divisia  indexes  grow  at  a  considerably  slower  rate 
than  do  the  fixed-veight  taspeyres  indexes  that  exclude  these  new  goods.  In 
the  pharmaceutical  industry,  the  role  of  new  and  relatively  young  goods  is  a 
significant  one,  and  failing  to  incorporate  new  goods  promptly  into  the  price 
index  calculations  results  in  upward  biased  growth  rates. 
VI.  QJLKLUDING RE!j,Q& 
Cur  focus  in  this  paper  has  been  on  why  the  official  BLS price  index 
grovs  approximately  50X  more  rapidly  (9.09X  vs.  6.03%)  than  a  Divisia  index, 
where  the  latter  is  computed  using  data  on  2,090  products  sold  by  four  of  the 
ten  largest  firms  in  the  US pharmaceutical  industry.  These  four  firms 
comprised  approximately  24% of  total  domestic  industry  sales  in  1989. 
The  evidence  we have  presented  suggests  that,  in  terms  of  sampled  items, 
the  difference  cannot  be  attributed  to  the  four  firms  being  unrepresentative  of 
the  industry  as  a  vhole,  for  growth  rates  of  prices  for  items  sampled  by  the 
BLS  at  the  four  firms  are  very  close  to  that  of  the  official  PPI  (8.94X  VS. 
9.09X).  Moreover,  when  IIIS  data  are  employed  for  a  sub-class  of  products 
(systemic  anti-infectives)  encompassing  almost  the  entire  universe  of  products, 
the  difference  in  AAGR becomes even  larger  --  6.26X  for  the  official  PPI  vs. 
1.54’2  for  the  Divisia  index,  An  incidental  finding  is  that  for  the  241  exact 
product  matches  betveen  the  IHS  and  four-company  data  sets,  growth  rates  of 
prices  are  similar  --  a  similarity  that  gives  us  some  confidence  in  using  the AUDITING  THE  PRODUCER  PRICE  INDEX  -  Page  27  - 
IHS  data  aa  a  proxy  for  producer  level  price  growth.  Finally,  differences 
bctveen  industry-wide  and  the  four-firm  product  share  distributions  do  not  help 
explain  the  discrepancy,  for  differentials  in  MCR’s  are  essentially  unaffected 
vhen  Census-BLS  industry  sub-class  weights  are  employed  instead  of  those  based 
on  the  four-firm  dats. 
What  IS  it  about  the  BLS  procedures  that  on  average  appear  to  miss  the 
smaller  price  increases  of  representative  transactions7  Our  analysis  has 
demonstrated  that  a  substantial  proportion  (about  50X)  of  the  difference  in 
MCR’s  bctveen  prices  reported  by  the  four  firms  to  the  BL5  and  transactions 
prices  for  the  four-firm  universe  of  products  can  be  attrfbuted  to  the  fact 
that  the  BLS  tends  to  undersample  younger  products  that  experience  less  than 
average  pries  increases,  and  oversample  medium-age  items  that  undergo  above- 
average  price  increases,  Uhy  it  is  that  the  BlS  undersaaples  younger  and 
oversamples  medium-age  products  is  not  clear  to  us,  nor  do  ve  address  in  this 
paper  the  interesting  issue  of  vhy  medium-age  products  experience  larger  price 
increases  than  younger  items. 
We  also  find  that  differences  in  AAGRs  betveen  the  Laspeyres  and  Divisia 
indexes  are  rather  modest  provided  that  computations  are  undertaken  over  an 
identical  set  of  goods,  Hovever,  vhen  the  set  of  goods  included  in  the 
computations  incorporates  new  and  relatively  young  products,  the  resulting 
Divisia  price  indexes  grow  at  a  considerably  slover  rate  than  do  the  fixed- 
weight  Lspeyres  price  indexes.  In  the  US  pharmaceutical  industry  from  1964 
through  1989,  the  role  of  new  and  relatively  young  goods  was  a  significant  one, 
and  failing  to  incorporate  new  goods  promptly  into  the  price  index  calculations 
appears  to  have  resulted  in  upvard  biased  growth  rates. 
It  is  worth  emphasizing  that  the  research  reported  here  neglects  entirely 
the  fact  that  generic  drugs  could  be  linked  to  their  patented  antecedents,  and 
that  new  drugs  incorporating  quality  changes  could  be  connected  to  their AUDITING  THE  PRODUCER  PRICE  INDEX  -  Pago  26  - 
predecessors  vim  hedonic  procedurer.25  Since  generic  drugs  ara  treated  by  the 
BIS  AS  entirely  new  products  and  are  not  linked  to  petentrd  progenitors,  and 
since  generics  tend  initially  to  bo  priced  at  lover  levels  than  thrir  patented 
comprtitors,  ve  believe  that  the  MCR’s  of  price  indexes  properly  linking 
generics  vould  be  even  lover  than  those  reported  in  this  paper.  Work  on  this 
issue  is  currently  underway  involving  systemic  anti-infectives,  as  is  an 
exploratory  effort  to  determine  vhether  it  is  feasible  to  undertake  hedonic 
price  analysis  for  cardiovascular  drugs. AUDITING  THE  PRODUCER  PRICE  INDEX  -  Page  29  - 
APPENDIX  A: 
FURTHER  DETAILS  ON  THE  PRODUCER  PRICE  INDEX  FOR  SIC  28361 
Before  1978  the  Producer  Price  Index  vas  known  as  the  Wholesale  Price 
Index  (UPI).  The  UPI  originated  from  an  1891  U.S.  Senate  rcsolutlon 
authorizing  the  Senate  Committee  on  Finance  to  investigate  the  effects  of  the 
tariff  lavs  “upon  the  imports  and  exports,  the  grovth,  development,  and  prices 
of  agricultural  and  manufactured  articles  at  home  and  abroad.  “26 
The  BLS calulates  the  PPI  according  to  a  modified  Lsspeyres  formula  in 
vhlch  the  value  of  base  period  quantities  at  current  period  pricer  1s dlvlded 
by  the  value  of  base  period  quantities  at  (perhaps  temporally  different)  base 
period  prices,  i.e., 
It  -  ( 1 QaPt  /  1  QaPD1*lOO  -  [  Cc  Q,P,(P,/P,W  1  QaPol*lW  (1) 
vhere  Qa  represents  the  quantity  shipped  during  the  velght-base  period,  P,  10 
the  current  price  of  the  commodity,  PO  is  the  price  of  the  commodity  in  the 
comparison  period,  the  summation  is  over  i  goods,  but  1  subscripts  are 
oaltted.27  Note  that  this  index  is  a  weighted  average  of  price  relatives 
In  the  main  text  of  this  paper  ve  outlined  the  process  employed  by  the 
BLS  in  choosing  establishments  and  products  to  sample.  To  understand  this 
sampling  process  better,  ve  now  follow  the  BLS procedure  and  discuss  its  two 
distinct  stages,  in  vhich  the  overall  aim  is  to  make  the  probability  of 
selection  proportional  to  a  product’s  value  of  shipments  (VOS).  The  first 
stage  consists  of  choosing  a  random  sample  of  establishments,  drawn  from 
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producta  of  that  l stabllshmsnt  are  chosen  wlth  probability  proportional  to  VOS, 
although  in  practice  some  products  for  SIC  2834  sro  certsinty  selectd  to 
ensure  coverage  of  important  items.  28  We  now  summarize  these  two  stages. 
~11  PPI’s  are  routinely  subject  to  monthly  revision  every  month  for  four 
months  after  original  publication  (usually  on  the  second  or  third  Friday  of  the 
month  following  the  reference  month),  to  reflect  late  reportr  and  corrections 
by  compsny  respondents.  After  four  months,  indexes  are  considered  final. 
The  sampling  frame  for  estsbllshments  is  drawn  from  the  Unemployment 
Insurance  data  files  (as  upd.sted  and  refined  by  BLS personnel),  and  in  almost 
all  cases  reported  employment  determines  the  probability  of  inclusion.  29 
Although  use  of  VOS  to  choose  the  establishment  sampling  frsme  would  be 
preferable,  the  BLS Justifies  using  employment  as  a  proxy  for  VOS  in  the  first 
stage  since  employment  figures  are  more  widely  available  for  estebllshments 
than  sre  data  on  VOS;  3o  moreover,  BLS asserts  that  UI  ‘...ls  used  as  a  proxy  in 
sampling  since  the  number  of  employees  tends  to  be  correlated  with  the  revenue 
of  a  Profit  Haxlmltlng  Center  within  a  particular  SIC.“31  If  prices  for 
several  establishments  are  set  at  one  location  (called  a  Profit  Haxlnlrlng 
Center),  then  the  estsbllshments  (referred  to  as  a  cluster)  are  considered  to 
be  one  establishment,  and  the  reported  employment  figures  are  appropriately 
summed. 
Once  an  establishment  has  been  selected,  in  the  second  stage  l  BLS  field 
representative  visits  it  and  conducts  an  interview  designed  to  select  the  items 
to  be  priced  and  to  collect  base  prices  and  value  weights.  In  theory,  the 
probability  with  which  a  product  is  selected,  given  choice  of  the  establishment 
and  the  number  of  quotes  asslgned  to  it,  is  proportional  to  its  VOS  over  the 
twelve  months  prior  to  the  interview.  In  this  dlsaggregatlon  process,  ln 
principle,  VOS-based  sampling  probabilities  are  employed,  but  detalled 
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subset  of  products.  This  economy  of  required  detail  reduces  the  reporting 
burden  on  cooperating  companies,  and  results  in  an  initiation  interview  that  is 
“usually  completed  within  2  hours.  “32 
Within  the  disaggregation  process,  several  additional  steps  occur. 
First,  all  products  are  categorized  into  broad  product  classes.  A  running 
total  of  the  percent  of  VOS  for  each  category  is  formed,  and  the  number  of 
price  quotes  to  be  taken  from  within  each  category  is  determined  by  randomly 
choosing  a  first  percentile  level  and  equally  spacing  the  remaining  quotes  to 
be  chosen. 
For  example,  suppose  there  are  three  product  categories  and  that  five 
quotes  are  to  be  chosen  for  the  establishment  as  a  whole.  Let  the  first 
category  account  for  SOX of  the  VOS,  the  second  for  30X.  and  the  third  for  20X; 
hence  the  running  total  is  SOX,  BOX  and  100X.  Since  five  quotes  are  to  be 
chosen,  a  random percentile  level  from  1  to  20  is  selected  (note  that  100X/S  - 
20X).  Suppose  this  random percentile  level  is  1S.33  Then  the  additional  four 
quotes  are  equally  spaced  at  intervals  of  20;  in  this  case,  at  3S,  55,  75  and 
9s.  because  the  15th  and  35th  percentiles  both  fall  within  the  first  segment 
of  the  running  total  (OX  -  SOX),  tvo  quotes  will  be  chosen  from  the  first 
category.  Similarly,  55  and  7S  fall  within  the  second  segment,  so  two  quotes 
~111  be  chosen  from  the  second  category.  Finally,  one  quote  will  come from  the 
third  category.  This  process  of  disaggregation  is  repeated  within  each 
category  from  the  first  stage  until  an  individual  product  involved  in  a 
particular  transaction  is  identified.  The  resulting  unique  transaction  is  then 
recorded  in  detail  so  that  future  price  quotes  can  be  accurately  identified  by 
the  reporting  establishment. 
As  was noted  earlier,  in  some cases  selected  product  categories  are 
-certainty  sampled’  or  “certainty  selected”.  This  can  occur  if  it  is  felt  by 
the  BLS  that  some item  is  of  particular  importance,  or  may  be  so  in  the  future. i 
8 
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1 
In  the  1987  sample  for  specified  companies,  both  diabetes  and  cancer  therapies 
are  certainty  selected.  In  this  type  of  certainty  selection,  one  item  from 
! 
within  the  chosen  category  is  selected  using  normal  disaggregation  procedures 
(e.g.,  vithin  SIC  2834  119  for  cancer  therapies,  or  vithin  SIC  2834  127  for 
diabetes  therapies),  the  VOS for  the  entire  category  is  subtracted  from  the  VOS 
of  the  establishment,  the  number  of  remaining  selections  is  reduced  by  one,  and 
the  disaggregation  process  is  begun  again  from  the  beginning  (without  the 
certainty  selected  category).  This  procedure  is  repeated  for  any  additional 
certainty  selected  items.  A  second  type  of  certainty  sampling  occurs  whenever 
the  percentage  of  VOS for  a  product  class  exceeds  the  sampling  interval  at  that 
level  of  disaggregotion. 
For  the  pharmaceutical  and  paper  mill  industries,  the  Cycle  II 
disaggregation  procedure  differed  from  that  for  most  other  industries  in  tvo 
respects.  First,  rather  than  alloving  the  establishment  to  determine  the 
classes  of  products  for  the  first  step  of  the  disaggregation  process,  the  BU 
provided  a  table  of  product  categories.  In  most  industrias  no  more  than  eight 
categories  are  defined  at  each  level  of  disaggregation.  but  in  SIC  28341  there 
are  48  products  vithin  the  prescription  pharmaceuticals  section.  The  other 
difference  from  normal  disaggregation  procedures  is  in  the  handling  of  the 
second  typo  of  certainty  selection,  mentioned  at  the  end  of  the  previous 
paragraph.  The  normal  disaggregation  procedure  might  result  in  *multiple 
hits”,  i.e.  it  might  choose  a  given  product  more  than  once.  To  avoid  this,  if 
a  category  is  vider  than  the  sampling  interval,  then  a  product  is  chosen  by 
disaggregation  vithin  the  category,  the  VOS  is  deducted  from  the  overall  VOS 
for  the  establishment,  and  the  process  is  started  again  vith  the  certainty 
selected  item  removed.  Hence  multiple  hits  are  not  po3sible.34 
Once  the  initiation  interviev  is  completed  and  the  items  for  vhich  price 
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taking  place  through  the  mail.  From  this  the  BLS obtains  a  time  series  of 
monthly  price  quotes  for  each  item  sampled,  defined  in  such  a  way  so  as  to  make 
the  item  transacted  and  the  transaction  constant  over  time. 
To  construct  PPI’s,  the  sampled  products  art  classified  into  cells, 
typically  at  the  seven  to  nine  digit  SIC  level;  the  within  cell  index  weights 
art  the  VOS  for  the  establishment  divided  by  the  number  of  quotes  from  the 
establishment.  Note  that  an  item  with  a  small  VOS  is  given  the  same vithin- 
cell  vtight  as  an  item  with  a  larger  VOS,  but  that  this  is  consistent  with 
probability  sampling  proportional  to  VOS,  for  the  small  item  essentially 
represents  many  other  small  items  which.  when  combined,  have  the  same 
probability  of  selection  as  a  single,  larger  item  with  the  same  VOS.  As  ve 
understand  it,  the  within  cell  index  is  a  fixed-base  Lasptyres  index  adjusted 
froo  uonth  to  month  so  as  to  shov  no  change  when  product  deletions  occur. 
Aggregated  between-cell  indexes  are  then  created  by  weighting  withln-cell 
indexes  by  VOS  within  the  cells  produced  vithin  the  same  industry;  these  VOS 
are  taken  from  the  U.S.  Department  of  Commerce.  Census  of  Hanufacturers.  35 
Thus,  shipment  values  for  the  same products  oade  in  other  industries  do  not 
enter  the  vtighting  structure.  36  The  total  value  of  shipments  for  each 
industry  is  then  distributed  among  the  products  or  other  revenue  sources 
produced  by  that  industry,  thereby  tlimtnating  the  need  for  indirect  weight 
imputations.  a  practice  that  vas  common  under  the  pre-1978  methodology  of  the 
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‘Iwing  Fisher  [1922),  p.  360. 
2Specifically,  fixed  weights  are  linked  in  January  1988,  corresponding  with 
the  BLS  chsngs  in  moving  from  Cycle  I  to  Cycle  XI  sampling. 
his  paper  extends  and  builds  on  the  preliminary  findings  and  conjectures 
reported  in  Berndt,  Grilichss  snd  Rosett  [1990]. 
4Thir  issue  has  been  examined  by  George  3.  Stiglrr  and  James K.  Kindahl 
[ 19701,  who  found  that  overall,  although  them  vas  little  difference  between 
the  trend  of  BLS and  transactions  prices  from  1957  to  1961,  from  1961  to  1966 
the  BLS price  index  rose  about  0.7X  more  rapidly  than  an  index  bssad  on 
transsctions  prices.  For  the  ethical  phsrmaceutical  praparstions  industry, 
however,  Stigler-Kindahl  found  no  sppreciablo  difference  brtvern  BI.S  and 
transactions  prices. 
%luch  of  the  material  in  this  Appendix  is  taken  from  Berndt,  Griliches  and 
Rosett  [ 19901. 
‘Some  products  uere  deleted  from  or  added  to  this  list  during  the  1984-89  time 
period. 
‘There  is  some confusion  concerning  the  treatment  of  production  in  Puerto 
Rico.  A  substsncial  amount  of  pharmaceutical  preparations  production  occurs 
in  Puerto  Rico,  and  while  production  establishments  are  not  sampled  by  the  BlS 
in  Puerto  Rico,  from  conversations  with  company  officials  vs  ar:,  lad  to 
belirvo  that  in  reporting  data  to  the  BLS  the  firms  treat  Puerto  Rico  as 
domestic. 
‘Sinca  no  industry  publication  provides  a  classification  of  prescription 
phsrmacruticals  by  7-digit  SIC  code,  we uorkbd  vith  conpsny  officials  and 
examined  thr  Physicians’  Desk  Refarance  (19901  and  Drug  Facts  and  Comparisons 
(19911  in  undertaking  such  a  clsssification.  In  some cases,  however,  judgment 
was nrcassary,  for  occasionally  a  drug  could  be  snvisaged  as  being  in  more 
than  ons  sub-class.  Overall  price  and  sales  data  vero  given  us  for  2,551 
products,  of  which  207  were  classified  as  non-prescription.  In  addition,  vo 
were  unsblr  to  assign  dstailed  SIC  clsssss  for  254  products.  The  non- 
proscription  items  accounted  for  only  1.10X  of  total  revenues,  and  the 
unclassified  items  accounted  for  but  0.53X  of  tots1  revenues. 
‘IHS  borica,  660  U.  Germantown  Pike,  Plymouth  Meeting,  Pcnnsylvsnia  19462 
(telephone  215-834-5000). 
.  “This  discussion  is  bared  in  large  part  on  summary  information  provided  us  by 
IHS  America  in  the  “front  pager”  of  audit  information  for  U.S.  Drugstore  and 
U.S.  Hospital. 
“Average  prices  are  often  lower  to  hospitals  than  to  other  outlets. 
120vrrall,  341  matches  were  made between  IMS  and  4-company  products.  100  were 
deleted,  AS  45  had  no  common-month prices,  38  had  few  and  highly  volatile 
prices  reported  by  the  companies,  and  17  were  entrants  or  exits  where 
movements  of  initial  or  final  sales  by  producers  through  the  distribution 
chain  caused  poor  contemporaneous  tracking  in  the  MS  data. 
13’Ihe  AMR  of  the  Divisia  index  (using  four-company  revenue  weights)  for  IKS AUDITING  THE  PRODUCER  PRICE  INDEX  -  Page  35  - 
data  was  4.12X,  while  that  for  the  matched  four-company  products  was  3.27X. 
Since  the  four-company  Divisia  for  all  products  in  SIC  2834111  grows  at  but 
1.20X  per  year,  we  interpret  the  higher  growth  rates  of  these  common  items.as 
reflecting  the  fact  that  the  matched  products  omit  new  goods  and  therefore 
represent  more  mature,  established  products.  Recall  from  the  previous 
footnote  that  typically  nev  goods  are  poorly  tracked  by  IMS  as  they  initially 
enter  the  distribution  chain. 
141t  might  be  noted,  however,  that  contemporaneous  correlations  of  monthly  log 
price  changes  between  IHS  and  company  data  are  typically  very  low  --  often 
less  than  0.02.  However,  for  annualized  prices,  the  revenue-weighted 
correlations  exceed  0.5. 
15Paralle1  MCR’s  over  the  same lo/84  -  12/89  time  period  for  the  four-company 
products  in  SIC  2834111  are  1.96X  for  the  Laspeyres  and  1.15X  for  the  Divisia. 
Ue  had  expected  the  Ikf.9 prices  to  grow  at  a  slower  rate  than  those  in  the 
four-company  data,  in  part  because  the  ItlS  data  include  generic  drugs.  Why 
this  inequality  occurs  is  a  topic  worthy  of  further  consideration. 
16tlonthly  total  revenue  data  by  therapeutic  class  were  purchased  from  Ills. 
17This  smoothing  procedure  was employed  to  mitigate  the  problem  of  “drift 
that  occurs  with  chained  indexes  such  as  the  Divisia.  For  further  discussion, 
see  Berndt,  Griliches  and  Rosett  (19901,  as  well  as  Barzel  119631,  Frisch 
119361  and  Stulc  (19831. 
1’This  Laspeyres  calculation  uses  company  quantities  as weights,  and  links 
them  in  January  1988  to  reflect  the  BLS splice  between  Cycles  I  and  II.  For 
Cycle  I,  the  MGR  of  reported  prices  was 7.741.  while  for  transactions  prices 
it  was 8.97X;  for  Cycle  II,  the  respective  growth  rates  are  11.49X  and  10.69X. 
“For  Cycle  I,  reported  and  average  transactions  prices  of  SIC  2834111  sampled 
items  grew  at  an  MGR  of  7.64X  and  7.63X,  respectively,  while  for  Cycle  11  the 
growth  rates  are  10.43X  and  10.64X. 
2oSee,  for  example,  W.  Ervin  Dievert  (19881  and  the  references  cited  therein. 
21  Alternative  presentations  of  the  same  product  introduced  at  different  dates 
are  treated  as  such,  i.e.,  we  do  not  treat  alternative  treatments  as  all  being 
introduced  at  the  time  the  initial  presentation  was brought  to  market. 
22Revenue  shares  are  computed  as  the  arithmetic  mean of  the  shares  in  the  tvo 
years. 
23Uhen a  similar  analysis  is  done  separately  for  Cycles  I  and,  we  find  that  of 
the  1.16X  difference  in  MCR  in  Cycle  I,  the  right-hand  side  of  equation  (4) 
explains  1.57X  (or  more  than  the  entire  difference),  while  in  Cycle  II  the. 
relationship  explains  1.15X  of  the  4.60X  difference  in  AACR’o. 
241t  would  have  been  desirable  to  undertake  a  similar  analysis  using  the  IhS 
data,  but  at  this  point  in  time  we have  not  been  able  to  obtain  data  on 
product  introduction  dates  for  the  items  in  that  data  set. 
25For  an  example  in  the  context  of  personal  computers,  see  Berndt-Criliches 
[1990]. 
26See  U.S.  Senate  Committee  on  Finance  (1893). AUDITING  THE  PRODUCER  PRICE  INDEX  -  Page  36  - 
*‘Note  that  the  summation  counter  is  not  specified  in  (1),  and  generally 
requirer  an  additional  subscript.  Also,  the  BIS  Handbook  (BIS,  Bulletin  2265 
[1988],  p.  130)  states  that  ‘The  expression  (QaPD)  represents  the  weight  in 
value  form,  and  the  P  and  Q  elements  (both  of  which  originally  relate  to 
period  ‘a”  but  are  adjusted  for  price  change  to  period  “0”)  are  not  derived 
separately.” 
281n  U.  S.  Department  of  Labor  [undated,  a],  it  is  stated  that  “For  specified 
companies,  both  cancer  therapy  and  diabetes  preparation  drugs  are  being 
certainty  selected.” 
2gDiscussions  with  BLS personnel  indicate  that  in  some  cases  where  value  of 
shipment  data  is  intact  and  complete  for  establishments,  VOS rather  than  UI 
data  are  used  to  compute  probabilities  of  inclusion. 
3oAs Hill  [1987,  p.  5831  notes,  “By  law,  every  employor  in  the  U.S.  is 
required  to  report  the  number  of  people  employed  and  to  purchase  insurance 
vhich  vi11  cover  the  employer’s  unemployment  benefit  liability.  As  a  result 
the  UI  file  data  are  fairly  complete.  The  continued  existence  of  the  UI  file 
is  also  assured,  thereby  ensuring  continued  availability  of  a  consistent  frame 
for  sampling.  The  UI  file  contains  such  information  as  the  establishment’s 
name,  the  SIC  in  which  it  is  classified,  the  county  and  state  in  which  it  18 
located,  and  its  number  of  employees.  This  file  is  explicitly  stratified 
according  to  industry  classification  and  thus  provides  individual  industry 
frames  vhich  form  the  basis  for  the  PPI  frames.” 
%ill  119871,  p.  584. 
32U.  S.  Department  of  labor  11988,  p.  128). 
33Randoo numbers are  presented  on  the  bottoms  of  pages  in  the  forms  filled  out 
by  BLS  field  representatives. 
34Houever,  there  is  some ambiguity  here.  Although  the  wording  in  the  BLS 
discussion  of  special  disaggregation  procedurea  (U.  S.  Department  of  Labor 
[1986a])  explicitly  states  that  the  entire  cell  is  discarded  once  the 
certainty  selection  occurs,  our  sample  from  one  company  contains  multiple 
selections  from  individual  cells. 
35 An  adjustment  is  made for  inter-  and  intra-industry  transfers  to  remove  non- 
final  product  values  from  the  veights,  thereby  obtaining  net  output  values  of 
shipments  as  weights.  Currently  the  adjustment  factor  is  based  on  the  1977 
Input-Output  tables  from  the  Bureau  of  Economic  Analysis,  U.  S.  Department  of 
Commerce. 
36For  further  discussion,  see  U.  S.  Department  of  Labor  [1988,  p.  1291. AUDITING  THE  PRODUCER  PRICE  INDEX  -  Page  37  - 
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